First Trust Advisors LP Invitae Corp Transaction History

First Trust Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$2.13 - $9.01 $93,149 - $394,025	43,732 New	43,732 $107,000
Q2 2021 Aug 16, 2021	SELL	$26.09 - $40.4 $829,740 - $1.28 Million	-31,803 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$33.06 - $56.93 $1.92 Million - $3.31 Million	-58,133 Reduced 64.64%	31,803 $1.22 Million
Q4 2020 Feb 02, 2021	BUY	$39.09 - $57.4 $553,514 - $812,784	14,160 Added 18.69%	89,936 $3.76 Million
Q3 2020 Nov 05, 2020	BUY	$28.43 - $44.67 $666,370 - $1.05 Million	23,439 Added 44.78%	75,776 $3.29 Million

Q2 2020 Jul 22, 2020	BUY	$11.71 - $30.29 $440,424 - $1.14 Million	37,611 Added 255.41%	52,337 $1.59 Million
Q1 2020 May 06, 2020	SELL	$7.64 - $27.5 $147,482 - $530,860	-19,304 Reduced 56.73%	14,726 $201,000
Q4 2019 Feb 03, 2020	SELL	$15.02 - $20.57 $1.41 Million - $1.93 Million	-93,592 Reduced 73.34%	34,030 $549,000
Q3 2019 Nov 04, 2019	SELL	$18.85 - $27.5 $795,488 - $1.16 Million	-42,201 Reduced 24.85%	127,622 $2.46 Million
Q2 2019 Jul 30, 2019	BUY	$17.37 - $26.27 $2.95 Million - $4.46 Million	169,823 New	169,823 $3.99 Million

7.66M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.